Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 40

1.

Disseminated tumor cells in bone marrow and circulating tumor cells in blood of breast cancer patients: current state of detection and characterization.

Riethdorf S, Pantel K.

Pathobiology. 2008;75(2):140-8. doi: 10.1159/000123852. Epub 2008 Jun 10. Review.

PMID:
18544969
2.

Detection, clinical relevance and specific biological properties of disseminating tumour cells.

Pantel K, Brakenhoff RH, Brandt B.

Nat Rev Cancer. 2008 May;8(5):329-40. doi: 10.1038/nrc2375. Review.

PMID:
18404148
3.

Monitoring the response of circulating epithelial tumor cells to adjuvant chemotherapy in breast cancer allows detection of patients at risk of early relapse.

Pachmann K, Camara O, Kavallaris A, Krauspe S, Malarski N, Gajda M, Kroll T, Jörke C, Hammer U, Altendorf-Hofmann A, Rabenstein C, Pachmann U, Runnebaum I, Höffken K.

J Clin Oncol. 2008 Mar 10;26(8):1208-15. doi: 10.1200/JCO.2007.13.6523.

PMID:
18323545
4.

Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance.

Matsui W, Wang Q, Barber JP, Brennan S, Smith BD, Borrello I, McNiece I, Lin L, Ambinder RF, Peacock C, Watkins DN, Huff CA, Jones RJ.

Cancer Res. 2008 Jan 1;68(1):190-7. doi: 10.1158/0008-5472.CAN-07-3096.

5.

IgVH mutational status and clonality analysis of Richter's transformation: diffuse large B-cell lymphoma and Hodgkin lymphoma in association with B-cell chronic lymphocytic leukemia (B-CLL) represent 2 different pathways of disease evolution.

Mao Z, Quintanilla-Martinez L, Raffeld M, Richter M, Krugmann J, Burek C, Hartmann E, Rudiger T, Jaffe ES, Müller-Hermelink HK, Ott G, Fend F, Rosenwald A.

Am J Surg Pathol. 2007 Oct;31(10):1605-14.

PMID:
17895764
6.

Preparing the "soil": the premetastatic niche.

Kaplan RN, Rafii S, Lyden D.

Cancer Res. 2006 Dec 1;66(23):11089-93. Review.

7.

Pathobiology of classical Hodgkin lymphoma.

Tzankov A, Dirnhofer S.

Pathobiology. 2006;73(3):107-25. Review.

PMID:
17085956
8.

Enhancement of clonogenicity of human multiple myeloma by dendritic cells.

Kukreja A, Hutchinson A, Dhodapkar K, Mazumder A, Vesole D, Angitapalli R, Jagannath S, Dhodapkar MV.

J Exp Med. 2006 Aug 7;203(8):1859-65. Epub 2006 Jul 31.

9.

B-cell differentiation immunophenotypes in classical Hodgkin lymphomas.

Bai M, Panoulas V, Papoudou-Bai A, Horianopoulos N, Kitsoulis P, Stefanaki K, Rontogianni D, Agnantis NJ, Kanavaros P.

Leuk Lymphoma. 2006 Mar;47(3):495-501.

PMID:
16396774
10.

Molecular biology of Hodgkin's and Reed/Sternberg cells in Hodgkin's lymphoma.

Bräuninger A, Schmitz R, Bechtel D, Renné C, Hansmann ML, Küppers R.

Int J Cancer. 2006 Apr 15;118(8):1853-61. Review.

11.

Evidence of abortive plasma cell differentiation in Hodgkin and Reed-Sternberg cells of classical Hodgkin lymphoma.

Buettner M, Greiner A, Avramidou A, Jäck HM, Niedobitek G.

Hematol Oncol. 2005 Sep-Dec;23(3-4):127-32. Review.

PMID:
16342298
12.

VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche.

Kaplan RN, Riba RD, Zacharoulis S, Bramley AH, Vincent L, Costa C, MacDonald DD, Jin DK, Shido K, Kerns SA, Zhu Z, Hicklin D, Wu Y, Port JL, Altorki N, Port ER, Ruggero D, Shmelkov SV, Jensen KK, Rafii S, Lyden D.

Nature. 2005 Dec 8;438(7069):820-7.

13.

Epigenetic processes play a major role in B-cell-specific gene silencing in classical Hodgkin lymphoma.

Ushmorov A, Leithäuser F, Sakk O, Weinhaüsel A, Popov SW, Möller P, Wirth T.

Blood. 2006 Mar 15;107(6):2493-500. Epub 2005 Nov 22.

14.

Molecular pathogenesis of Hodgkin's lymphoma.

Re D, Küppers R, Diehl V.

J Clin Oncol. 2005 Sep 10;23(26):6379-86. Review.

PMID:
16155023
15.

Effects of imatinib and interferon on primitive chronic myeloid leukaemia progenitors.

Angstreich GR, Matsui W, Huff CA, Vala MS, Barber J, Hawkins AL, Griffin CA, Smith BD, Jones RJ.

Br J Haematol. 2005 Aug;130(3):373-81.

PMID:
16042686
16.

Circulating tumor cells in breast cancer: correlation to bone marrow micrometastases, heterogeneous response to systemic therapy and low proliferative activity.

Müller V, Stahmann N, Riethdorf S, Rau T, Zabel T, Goetz A, Jänicke F, Pantel K.

Clin Cancer Res. 2005 May 15;11(10):3678-85.

17.

Aplastic anaemia.

Brodsky RA, Jones RJ.

Lancet. 2005 May 7-13;365(9471):1647-56. Review.

PMID:
15885298
18.

Epigenetic silencing of the immunoglobulin heavy-chain gene in classical Hodgkin lymphoma-derived cell lines contributes to the loss of immunoglobulin expression.

Ushmorov A, Ritz O, Hummel M, Leithäuser F, Möller P, Stein H, Wirth T.

Blood. 2004 Nov 15;104(10):3326-34. Epub 2004 Jul 29.

19.

Characterization of clonogenic multiple myeloma cells.

Matsui W, Huff CA, Wang Q, Malehorn MT, Barber J, Tanhehco Y, Smith BD, Civin CI, Jones RJ.

Blood. 2004 Mar 15;103(6):2332-6. Epub 2003 Nov 20.

20.

A pilot study of rituximab in patients with recurrent, classic Hodgkin disease.

Younes A, Romaguera J, Hagemeister F, McLaughlin P, Rodriguez MA, Fiumara P, Goy A, Jeha S, Manning JT Jr, Jones D, Abruzzo LV, Medeiros LJ.

Cancer. 2003 Jul 15;98(2):310-4.

Supplemental Content

Support Center